KCM
ARQT icon

Kornitzer Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Kornitzer Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Buy
199,683
+23,813
+14% +$555K 0.11% 186
2026
Q1 		$4.14M Buy
175,870
+62,485
+55% +$1.59M 0.09% 211
2025
Q4 		$3.29M Buy
+113,385
New +$2.9M 0.07% 267

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kornitzer Capital Management's ARQT Position: Q2 2026 in Review

Kornitzer Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 14% in Q2 2026, buying an estimated $555K and bringing the position to 199,683 shares worth $5.24M. The position accounts for 0.11% of the portfolio, ranked #186.

Kornitzer Capital Management first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Kornitzer Capital Management held 199,683 shares of Arcutis Biotherapeutics worth $5.24M as of Q2 2026.
  • Kornitzer Capital Management bought 23,813 Arcutis Biotherapeutics shares in Q2 2026, an estimated $555K.
  • Arcutis Biotherapeutics made up 0.11% of Kornitzer Capital Management's portfolio in Q2 2026, its #186 holding.
  • Kornitzer Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.